ATLAS is an international randomised clinical trial to determine reliably the optimal duration of adjuvant tamoxifen in early breast cancer (see page 2 of the January 2004 newsletter). It is already established that about five years of tamoxifen provides a definite improvement in long-term survival and reduces the risk of recurrence and of developing a new cancer in the opposite breast. However, there is uncertainty about the optimal duration of tamoxifen and whether a woman should stop her tamoxifen after a few years or continue for several years longer (Lancet 2005; 365:1687-1717). With about 1 million women now taking adjuvant tamoxifen, this question is of major importance and must be addressed reliably through large-scale randomised evidence. The main focus of ATLAS is to establish whether 10 years of tamoxifen confers greater benefit overall than just 5 years of the same treatment. The results from ATLAS in combination with the other smaller trials of the same question (see page 2 of the January 2005 newsletter) will affect the management of hundreds of thousands of women worldwide and potentially could avoid several thousands of unnecessary deaths, and although this is a study of tamoxifen duration, its results will be relevant to the appropriate duration of other, newer, hormonal treatments. ATLAS has now completed its recruitment phase with over 15,000 women randomised making it the largest cancer treatment trial so far undertaken. See the latest ATLAS newsletter for more information.
Powerpoint presentation from latest ATLAS Steering Committee, (Microsoft Powerpoint format 2.2Mb) 24th September 2005
Address, telephone and fax details for the ATLAS Trial Office in Oxford
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) - http://www.ctsu.ox.ac.uk/projects/ebctcg.shtml
Last updated: 25th October, 2005